X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (305) 305
female (217) 217
index medicus (215) 215
male (211) 211
middle aged (207) 207
aged (202) 202
bendamustine hydrochloride (182) 182
oncology (179) 179
bendamustine (171) 171
hematology (152) 152
antineoplastic combined chemotherapy protocols - therapeutic use (150) 150
nitrogen mustard compounds - adverse effects (136) 136
adult (131) 131
rituximab (120) 120
treatment outcome (114) 114
antineoplastic combined chemotherapy protocols - adverse effects (113) 113
nitrogen mustard compounds - administration & dosage (110) 110
aged, 80 and over (103) 103
leukemia, lymphocytic, chronic, b-cell - drug therapy (88) 88
bendamustine hydrochloride - administration & dosage (87) 87
chemotherapy (83) 83
nitrogen mustard compounds - therapeutic use (83) 83
non-hodgkins-lymphoma (66) 66
bendamustine hydrochloride - adverse effects (63) 63
cancer (61) 61
lymphomas (58) 58
antineoplastic agents - adverse effects (57) 57
therapy (57) 57
care and treatment (56) 56
antineoplastic agents (55) 55
antimitotic agents (54) 54
disease-free survival (53) 53
plus rituximab (52) 52
recurrence (52) 52
antineoplastic agents - therapeutic use (51) 51
antineoplastic agents, alkylating - adverse effects (51) 51
rituximab - administration & dosage (51) 51
chronic lymphocytic-leukemia (50) 50
retrospective studies (50) 50
antineoplastic agents, alkylating - therapeutic use (49) 49
medicine & public health (46) 46
trial (46) 46
lymphoma, non-hodgkin - drug therapy (44) 44
multicenter (44) 44
chronic lymphocytic leukemia (42) 42
antineoplastic combined chemotherapy protocols - administration & dosage (41) 41
fludarabine (41) 41
pharmacology & pharmacy (41) 41
antibodies, monoclonal, murine-derived - administration & dosage (40) 40
drug administration schedule (40) 40
cyclophosphamide (39) 39
toxicity (38) 38
drug therapy (37) 37
bendamustine hydrochloride - therapeutic use (36) 36
lymphoma, b-cell - drug therapy (36) 36
neoplasm staging (36) 36
lymphoma (35) 35
multiple myeloma - drug therapy (35) 35
1st-line treatment (34) 34
efficacy (34) 34
survival (34) 34
clinical trials (33) 33
follow-up studies (33) 33
lymphoma, mantle-cell - drug therapy (32) 32
mantle cell (32) 32
antibodies, monoclonal, murine-derived - adverse effects (31) 31
multiple myeloma (31) 31
antineoplastic agents - administration & dosage (30) 30
combination (30) 30
leukemia (30) 30
phase-ii multicenter (30) 30
phase-ii (29) 29
antineoplastic agents, alkylating - administration & dosage (28) 28
indolent (28) 28
rituximab - adverse effects (28) 28
survival rate (27) 27
article (26) 26
bortezomib (26) 26
dosage and administration (26) 26
neoplasm recurrence, local - drug therapy (26) 26
remission induction (26) 26
salvage therapy (26) 26
cll (25) 25
hemic and lymphatic diseases (25) 25
prognosis (24) 24
cyclophosphamide - administration & dosage (23) 23
relapse (23) 23
stem-cell transplantation (23) 23
analysis (22) 22
follicular lymphoma (22) 22
mantle cell lymphoma (22) 22
research (22) 22
lymphoma, follicular - drug therapy (21) 21
nitrogen mustard compounds - pharmacokinetics (21) 21
dose-response relationship, drug (20) 20
drug resistance, neoplasm (20) 20
indolent b-cell (20) 20
kaplan-meier estimate (20) 20
refractory indolent (20) 20
young adult (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (306) 306
German (6) 6
Japanese (3) 3
Russian (2) 2
Chinese (1) 1
French (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Life Sciences | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 57 - 66
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 27, pp. 3293 - 3299
Journal Article
Blood, ISSN 0006-4971, 10/2016, Volume 128, Issue 14, pp. 1814 - 1820
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 60, pp. 154 - 165
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4119 - 4126
Purpose: The PARP inhibitor veliparib enhances the cytotoxicity of alkylating agents. This phase I study evaluated veliparib with the bifunctional alkylator... 
MULTIPLE-MYELOMA | REFRACTORY INDOLENT | MANTLE-CELL | POLY(ADP-RIBOSE) POLYMERASE | ONCOLOGY | MALIGNANT-LYMPHOMA | MULTICENTER PHASE-II | METASTATIC BREAST-CANCER | PLUS RITUXIMAB | NON-HODGKINS-LYMPHOMA | RELAPSED INDOLENT | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Bendamustine Hydrochloride - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rituximab - administration & dosage | Disease-Free Survival | Bendamustine Hydrochloride - administration & dosage | Maximum Tolerated Dose | Benzimidazoles - administration & dosage | Lymphoma, B-Cell - pathology | Adult | Female | Aged | Benzimidazoles - adverse effects | Lymphoma, B-Cell - drug therapy | Rituximab - adverse effects | Toxicity | Multiple myeloma | Cytotoxicity | Alkylation | Quality | Safety engineering | Hypophosphatemia | Expansion | Neutropenia | Hypertension | Thrombocytopenia | Leukopenia | Anemia | Alkylating agents | Rituximab | Poly(ADP-ribose) polymerase | Nausea | Pharmacology | Patients | Lymphoma | Inhibitors | Lymphocytes B | Lymphopenia | Experimental design | Lymphomas | Pharmacokinetics | Cancer | B-cell lymphoma | Index Medicus | veliparib | PARP | rituximab | lymphoma | bendamustine
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 02/2015, Volume 56, Issue 2, pp. 347 - 352
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 4, Issue 1, pp. e15 - e23
Journal Article
Annals of Oncology, ISSN 0923-7534, 07/2016, Volume 27, Issue 7, pp. 1317 - 1323
Journal Article
Journal Article